Inflammatory Biomarkers As Predictors of Immune Activation to Different Irradiated Sites and Short-term Efficacy in Advanced Squamous Cell Esophageal Carcinoma Received Radioimmunotherapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 May 26

PMID 37234974

Authors

Mengying Li

Guoxin Cai

Zhenhua Gao

Xue Meng

Xiao Han

Affiliations

Soon will be listed here.

Abstract

Purpose: The present study aimed to compare immune activation among different irradiated sites and identify potential short-term efficacy prognostic factors in patients with advanced squamous cell esophageal carcinoma (ESCC) who received radiotherapy (RT) and immunotherapy.

Patients And Methods: We recorded the clinical characteristics, blood cell counts, and derived blood index ratios, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), at three time points (before, during, and after RT) in 121 patients with advanced ESCC who had received RT and immunotherapy. Chi-square test and univariate and multivariate logistic regression analyses were used to calculate the relationships among inflammatory biomarkers (IBs), irradiated sites, and short-term efficacy.

Results: Delta-IBs were calculated as (medio-IBs - pre-IBs) ÷ pre-IBs. The medians of delta-LMR, and delta-ALC were the highest, whereas the median of delta-SII was the lowest in patients with brain radiation. Treatment responses were observed within 3 months after RT or until the beginning of the next line therapy, and the disease control rate (DCR) was 75.2%. The areas under the receiver operating characteristic curve (AUCs) for delta-NLR and delta-SII were 0.723 (p = 0.001) and 0.725 (p < 0.001), respectively. Multivariate logistic regression analysis showed that the treatment lines of immunotherapy (odds ratio [OR], 4.852; 95% confidence interval [CI], 1.595-14.759; p = 0.005) and delta-SII (OR, 5.252; 95% CI, 1.048-26.320; p = 0.044) were independent indicators of short-term efficacy.

Conclusion: In this study, we found that RT to the brain had a stronger immune activation effect than RT to extracranial organs. We also found that earlier-line immunotherapy plus RT and a decrease in SII during RT may generate better short-term efficacy in advanced ESCC.

References

Biswas T, Kang K, Gawdi R, Bajor D, Machtay M, Jindal C . Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int J Environ Res Public Health. 2020; 17(21). PMC: 7662688. DOI: 10.3390/ijerph17217995. View

Zeng J, See A, Phallen J, Jackson C, Belcaid Z, Ruzevick J . Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013; 86(2):343-9. PMC: 3963403. DOI: 10.1016/j.ijrobp.2012.12.025. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Stoiber D, Assinger A . Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells. 2020; 9(4). PMC: 7226828. DOI: 10.3390/cells9040855. View

McGee H, Daly M, Azghadi S, Stewart S, Oesterich L, Schlom J . Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018; 101(5):1259-1270. PMC: 6364565. DOI: 10.1016/j.ijrobp.2018.04.038. View

Hoshino S, Takeuchi M, Kawakubo H, Matsuda S, Mayanagi S, Irino T . Usefulness of Neutrophil to Lymphocyte Ratio at Recurrence for Predicting Long-Term Outcomes in Patients with Recurrent Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2021; 28(6):3001-3008. DOI: 10.1245/s10434-021-09637-0. View

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R . Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2):687-95. PMC: 3904601. DOI: 10.1172/JCI67313. View

Wang L, Wang C, Wang J, Huang X, Cheng Y . A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017; 143(10):2077-2086. DOI: 10.1007/s00432-017-2451-1. View

Smyth M, Ngiow S, Ribas A, Teng M . Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2015; 13(3):143-58. DOI: 10.1038/nrclinonc.2015.209. View

10.

Hao J, Lin D, Dinh H, Mayakonda A, Jiang Y, Chang C . Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016; 48(12):1500-1507. PMC: 5127772. DOI: 10.1038/ng.3683. View

11.

Wu M, Liu J, Wu S, Liu J, Wu H, Yu J . Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Immunol. 2021; 12:803247. PMC: 8712862. DOI: 10.3389/fimmu.2021.803247. View

12.

Falcke S, Ruhle P, Deloch L, Fietkau R, Frey B, Gaipl U . Clinically Relevant Radiation Exposure Differentially Impacts Forms of Cell Death in Human Cells of the Innate and Adaptive Immune System. Int J Mol Sci. 2018; 19(11). PMC: 6274975. DOI: 10.3390/ijms19113574. View

13.

Gao Y, Guo W, Cai S, Zhang F, Shao F, Zhang G . Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019; 10(14):3188-3196. PMC: 6603384. DOI: 10.7150/jca.30281. View

14.

Sharabi A, Nirschl C, Kochel C, Nirschl T, Francica B, Velarde E . Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2014; 3(4):345-55. PMC: 4390444. DOI: 10.1158/2326-6066.CIR-14-0196. View

15.

Sun Y, Zhang L . The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res. 2018; 10:6167-6179. PMC: 6257133. DOI: 10.2147/CMAR.S171035. View

16.

Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G . Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. Oncologist. 2021; 26(7):e1110-e1124. PMC: 8265339. DOI: 10.1002/onco.13797. View

17.

Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z . The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2018; 234(2):1794-1802. DOI: 10.1002/jcp.27052. View

18.

Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M . Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma. Onco Targets Ther. 2023; 16:263-273. PMC: 10103711. DOI: 10.2147/OTT.S404926. View

19.

Seliger B, Massa C . Immune Therapy Resistance and Immune Escape of Tumors. Cancers (Basel). 2021; 13(3). PMC: 7867077. DOI: 10.3390/cancers13030551. View

20.

Liang H, Peng H, Chen L . Prognostic Value of Sarcopenia and Systemic Inflammation Markers in Patients Undergoing Definitive Radiotherapy for Esophageal Cancer. Cancer Manag Res. 2021; 13:181-192. PMC: 7810973. DOI: 10.2147/CMAR.S288522. View